替罗非班用于急性ST段抬高心肌梗死介入治疗的疗效观察

目的观察替罗非班用于急性ST段抬高心肌梗死（STEMI）行急诊直接经皮冠状动脉介入治疗（PCI）患者的有效性及安全性。方法将71例STEMI患者按数字表法随机分为替罗非班组（25例）和未使用替罗非班的对照组（46例），比较两组术后心肌梗死溶栓试验（TIMI）血流、随访住院期间和术后左室射血分数（LVEF）、主要不良心血管事件（MACE）发生率。结果替罗非班组与对照组比较术后TIMI血流差异有统计学意义（P〈0．05）；住院期间两组LVEF、MACE差异有统计学意义（均P〈0．05）；随访30d两组LVEF、MACE差异有统计学意义（均P〈0．05）；随访180d两组比较LVEF有所升高，MACE有所下降，但差异无统计学意义（P〉0．05）。结论替罗非班治疗急性STEMI患者有较好的临床疗效，且安全性好。

Clinical Observation of primary percutaneous coronary intervention combined with tirofiban therapy in treatment patients with acute ST-segment elevation myocardial infarction

Objective This study was conducted to investigate the clinical outcomes and safety of primary percutaneous coronary intervention(PCI) combined with tirofiban therapy in patients with acute ST segment elevation myocardial infarction(STEMI). Methods Seventy-one consecutive patients with acute STEMI were divided by random number table to primary PCI combined with tirofiban therapy group(Tirofiban group,25 cases) and primary PCI treatment alone group(Control group,46 cases). Left ventricular ejection fraction(LVEF) and major adverse cardiac events rates(MACE) during hospitalization period and at 30 days discharge and 180 days after discharge were compared between the two groups. Results TIMI grade flow was significantly different between the tirofiban group and control group after surgery. The LVEF and MACE were significantly different between two groups during hospitalization period and at 30 days after discharge. The MACE at 180 days followup was relatively reduced and LVEF was relatively improved in tirofiban group, but there was not significantly different. Conclusion Adjunctive therapy with tirofiban for patients with acute STEMI who underwent primary PCI was safe and effective.